Evidence map›Paper›PMID 41146877›Full record

ArticleMolecular therapy. Methods & clinical development2025

Heavy-chain immunoglobulin locus editing in rhesus macaque B cells to confer antibody production.

Anne-Sophie Kuhlmann, Nawal Madkhali, Eliana Moskovitz, Jacob E Parrott, Shruthi Shankar Raman, Andrew O Riker, Jasmin Martinez-Reyes, Megha Gupta, Ryan An Jang, Veronica Nelson and 4 more

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Toward CAR-B cells for HIV-1 therapy.Molecular therapy. Methods & clinical development · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anne-Sophie KuhlmannDivisions of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.
Nawal MadkhaliDivisions of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.
Eliana MoskovitzDivisions of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.
Jacob E ParrottDivisions of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.
Shruthi Shankar RamanDivisions of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.
Andrew O RikerDivisions of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.
Jasmin Martinez-ReyesDivisions of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.
Megha GuptaDivisions of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.
Ryan An JangDivisions of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.
Veronica NelsonDivisions of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.
Matthew D GrayDivisions of Vaccine Infectious Disease, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.
Justin J TaylorDivisions of Vaccine Infectious Disease, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.
Christopher W PetersonDivisions of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.
Hans-Peter KiemDivisions of Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109-1024, USA.

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
In Vivo Gene Editing of B cells with NICE-AAV VectorsR01AI167004 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Christopher W Peterson · 2022 to 2026
$3.7M
NIAID NIH HHS R01 AI167004NIH HHS P51 OD011092
6 · The paper itself

Abstract

Antibody-based immunotherapies are promising; however, their application remains limited to acute diseases due to rapid clearance of antibodies

Indexed as

B cellsbroadly neutralizing antibodiesCRISPRgene editingHIV-1NHPnonhuman primate

Identifiers

PMID41146877
PMCPMC12554106

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.